MedTrace Logo

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

NCT00238121 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2015-11-20

Study results available
· View outcomes & findings →

Summary

Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with advanced or recurrent uterine cancer.

Conditions

  • Recurrent Uterine Sarcoma
  • Stage III Uterine Sarcoma
  • Stage IV Uterine Sarcoma
  • Uterine Carcinosarcoma

Interventions

DRUG

sorafenib tosylate

Given orally

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Gini Fleming · University of Chicago Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238121 on ClinicalTrials.gov